Abiopharma

🔍 Saad Mark E (Executive)

Company: Axsome Therapeutics, Inc. (AXSM)

Report Date: 2025-09-05

Detailed Transactions and Holdings:

• Acquired 9,127 shares of Common Stock at $9.0 per share (Direct)
  Date: 2025-09-05 | Code: M | equity_swap_involved: false | shares_owned_after: 19,129.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,127 shares of Common Stock at $125.07 per share (Direct)
  Date: 2025-09-05 | Code: S | equity_swap_involved: false | shares_owned_after: 10,002.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-05 | Code: H | nature_of_ownership: See explanation 5 below. | shares_owned_after: 300.00 | Footnotes: F5
• Sold 9,127 shares of Stock Option (Right to Buy) at $9.0 per share (Derivative)
  Date: 2025-09-05 | Code: M | Expires: 2025-11-19 | Exercise: 2016-11-19 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within the next two months.
• F2: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.
• F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
• F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $125.00 and $125.22.
• F5: Represents additional shares held indirectly by the Reporting Person prior to September 5, 2025 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.